Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T30
- Development stage
- Unknown
- Lead developer
- PHCANN International
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
T30 is a high-potency medicinal cannabis product consisting of dried cannabis flower, developed and manufactured by PHCANN International. It is characterized by a high Delta-9-tetrahydrocannabinol (THC) content of approximately 30% (ranging from 27% to 33%) and a low cannabidiol (CBD) content of less than 1%. The product is cultivated indoors in EU GMP-certified facilities in North Macedonia and is non-irradiated. It is intended for therapeutic use via inhalation, typically through vaporization, for conditions where medical cannabis is prescribed, such as chronic pain, spasticity, or nausea, as determined by a prescribing clinician.
- Brand names
- T30T-30T 30
- Other names
- PHCANN T30PharmaCann T30
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on T30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T30.